You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

19 search results for: disease severity

expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

2 min

Dermatology

Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.

expert video

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

5 min

Rhinology

Prof. Mullol share his opinion on connection between loss of smell and sleep disorder in patients with CRSwNP.

Podcast

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients

15 min

Dermatology

Learn more about the journey to diagnosis for pediatric patients with AD in this conversation between Drs. Lisa Swanson and Weily Soong.

Infographic

Tools for Clinical Assessment of Prurigo Nodularis

17 min

Dermatology

An interactive guide that provides users with an overview of key assessment tools for Prurigo Nodularis clinical practice. Implementation of the most applied tools is exemplified via a patient case.

expert video

Current Treatment Landscape and Emerging Therapies

16 min

Dermatology

Dr. Lawrence F. Eichenfield reviews the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.

expert video

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

56 min

Dermatology

Experts discuss the latest evidence on how type 2 inflammation drives skin barrier dysfunction, affects the skin microbiome, and contributes to neuroimmune dysregulation in AD.

expert video

IgE as a Biomarker for Type 2 Asthma

14 min

Pulmonology

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region